![psa test ontario cost psa test ontario cost](https://i.pinimg.com/originals/a6/6a/5c/a66a5cc74be03f6322737e742d9f318b.jpg)
“Our results suggest that this novel blood test, based on, may offer a solution for this clinical unmet need,” See-Tong Pang said in a press release.
![psa test ontario cost psa test ontario cost](https://i0.wp.com/post.healthline.com/wp-content/uploads/2021/06/1251236-The-5-Best-At-Home-PSA-Test-Kits-of-2021-1296x728-Header-81b9bf.jpg)
Tests currently used to determine the need for biopsy, based on elevated PSA levels, have insufficient specificity and sensitivity, which leads to unnecessary biopsies in a large number of men. Some of these patients may require hospitalization. Unnecessary prostate biopsies present a significant risk for side effects, including fever, infection, and bleeding. Three out of four of these patients have a negative biopsy. 8.Ī significant number of men who undergo PSA screening receive an indeterminate, or “gray zone,” result. Researchers say the company’s circulating tumor cell (CTC) blood test could reduce the number of unnecessary biopsies by up to 90 percent.Ī study highlighting the test’s positive results, titled, “ Prospective clinical study of a prostate cancer (PCa) rule-out blood test for PSA gray zone patients using a sensitive circulating tumor cell assay,” was presented by lead author Jacob See-Tong Pang at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco, California, on Feb. A new, noninvasive blood test can reliably detect prostate cancer in patients with inconclusive PSA tests, the test’s developer, CellMax Life, recently announced.